You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,243,058


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,243,058
Title:BCMA antigen binding proteins
Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.
Inventor(s): Armitage; Richard J. (Bainbridge Island, WA), Blake; Michelle (Arlington, MA), Fanslow, III; William C. (Normandy Park, WA), O\'Neill; Jason Charles (Brier, WA), Kannan; Gunasekaran (Newbury Park, CA), Xu; Jiangchun (San Diego, CA), Tometsko; Mark Edward (Seattle, WA)
Assignee: Amgen, Inc. (Thousand Oaks, CA)
Application Number:14/098,275
Patent Claims:1. An isolated monoclonal antibody, or BCMA-binding fragment thereof, selected from the group consisting of: an antibody comprising a Vh-CDR1 comprising SEQ ID NO:4, a Vh-CDR2 comprising SEQ ID NO:5, a Vh-CDR3 comprising SEQ ID NO:6, a Vl-CDR1 comprising SEQ ID NO:106, a Vl-CDR2 comprising SEQ ID NO:107, and a Vl-CDR3 comprising SEQ ID NO:108; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:10, a Vh-CDR2 comprising SEQ ID NO:11, a Vh-CDR3 comprising SEQ ID NO:12, a VL-CDR1 comprising SEQ ID NO:112, a Vl-CDR2 comprising SEQ ID NO:113, and a Vl-CDR3 comprising SEQ ID NO:114; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:16, a Vh-CDR2 comprising SEQ ID NO:17, a Vh-CDR3 comprising SEQ ID NO:18, a Vl-CDR1 comprising SEQ ID NO:118, a Vl-CDR2 comprising SEQ ID NO:119, and a Vl-CDR3 comprising SEQ ID NO:120; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:22, a Vh-CDR2 comprising SEQ ID NO:23, a Vh-CDR3 comprising SEQ ID NO:24, a Vl-CDR1 comprising SEQ ID NO:124, a Vl-CDR2 comprising SEQ ID NO:125, and a Vl-CDR3 comprising SEQ ID NO:126; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:28, a Vh-CDR2 comprising SEQ ID NO:29, a Vh-CDR3 comprising SEQ ID NO:30, a Vl-CDR1 comprising SEQ ID NO:130, a Vl-CDR2 comprising SEQ ID NO:131, and a Vl-CDR3 comprising SEQ ID NO:132.

2. The antibody or fragment of claim 1, wherein said antibody or fragment is human.

3. The antibody or fragment of claim 1, wherein said antibody or fragment is a chimeric monoclonal antibody.

4. The antibody or fragment of claim 1, wherein said antibody or fragment further comprises a linker.

5. The antibody or fragment of claim 4, wherein said antibody or fragment further comprises a drug or chemotherapeutic agent.

6. The antibody or fragment of claim 5, wherein said antibody or fragment further comprises a linker selected from the group consisting of: 6-maleimidocaproyl, maleimidopropanoyl, valine-citrulline, alanine-phenylalanine, p-aminobenzyloxycarbonyl, Mal-dPEG4-NHS, N-succinimidyl 4-(2-pyridylthio)pentanoate ("SPP"), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate ("SMCC" or "MCC"), and N-succinimidyl (4-iodo-acetyl)aminobenzoate ("SIAB").

7. The antibody or fragment of claim 6, wherein said antibody or fragment further comprises a linker wherein said linker is N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate ("SMCC" or "MCC").

8. The antibody or fragment of claim 6, wherein said antibody or fragment further comprises a drug or chemotherapeutic agent selected from the group consisting of: thiotepa and cyclophosphamide (CYTOXAN.TM.); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics, such as the enediyne antibiotics (e.g. calicheamicin, especially calicheamicin .gamma1 and calicheamicin theta I, see, e.g., Angew Chem. Intl. Ed. Engl. 33:183-186 (1994); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin; chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, nitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites, such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues, such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs, such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens, such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals, such as aminoglutethimide, mitotane, trilostane; folic acid replenisher, such as frolinic acid; aceglatone;aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids, such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK.RTM.; razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOL.TM., Bristol-Myers Squibb Oncology, Princeton, N.J.) and doxetaxel (TAXOTERE.RTM., Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoic acid; capecitabine; tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens, such as flutamide, nilutamide, bicalutamide, leuprolide, goserelin, Colchicine-site Binders (Curacin), Combretastatins (AVE806, Combretastatin A-4 prodrug (CA4P), Oxi-4503), Cryptophycins (LY355703), Discodermolide, Dolastatin and Analogs (Auristatin PHE, Dolastatin 10, ILX-651, Symplostatin 1, TZT-1027), Epothilones (BMS-247550, BMS-310705, EP0906, KOS-862, ZK-EPO), Eleutherobin, FR182877, Halichondrin B (E7389), Halimide (NPI-2352 and NPI-2358), Hemiasterlins (HTI-286), Laulimalide, Maytansinoids ("DM1," "DM3" or "DM4") (Bivatuzumab mertansine, Cantuzumab mertansine, huN901-DM1/BB-10901TAP, MLN591DM1, My9-6-DM1, Trastuzumab-DM1), PC-SPES, Peloruside A, Resveratrol, S-allylmercaptocysteine (SAMC), Spongistatins, Vitilevuamide, Molecular Motor-Kinesins (SB-715992), Designed Colchicine-Site Binders (A-289099, A-293620/A-318315, ABT-751/E7010, D-24851/D-64131, ZD6126), Other Novel Spindle Poisons (2-Methoxyestradiol (2-ME2), Bezimidazole Carbamates (ANG 600 series, Mebendazole), CP248/CP461, HMN-214, R440, SDX-103, T67/T607).

9. The antibody or fragment of claim 8, wherein said drug or chemotherapeutic agent is selected from the group consisting of: Maytansinoids ("DM1," "DM3" or "DM4").

10. The antibody or fragment of claim 9, wherein said drug or chemotherapeutic agent is DM1.

11. The antibody or fragment of claim 10, wherein said antibody or fragment has a drug to antibody ratio of between 1 and 10.

12. The antibody or fragment of claim 11, wherein said antibody or fragment has a drug to antibody ratio of between 2 and 5.

13. A pharmaceutical composition comprising the antibody or fragments thereof of claim 12.

14. The pharmaceutical composition of claim 13 further comprising a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, and/or a preservative.

15. An isolated polynucleotide, wherein said polynucleotide encodes the antibody or fragment thereof of claim 1.

16. The polynucleotide of claim 15, wherein said polynucleotide sequence is selected from the group consisting of: a Vh-CDR1 comprising SEQ ID NO:1, a Vh-CDR2 comprising SEQ ID NO:2, a Vh-CDR3 comprising SEQ ID NO:3, a Vl-CDR1 comprising SEQ ID NO:103, a Vl-CDR2 comprising SEQ ID NO:104, and a Vl-CDR3 comprising SEQ ID NO:105; a Vh-CDR1 comprising SEQ ID NO:7, a Vh-CDR2 comprising SEQ ID NO:8, a Vh-CDR3 comprising SEQ ID NO:9, a Vl-CDR1 comprising SEQ ID NO:109, a Vl-CDR2 comprising SEQ ID NO:110, and a Vl-CDR3 comprising SEQ ID NO:111; a Vh-CDR1 comprising SEQ ID NO:13, a Vh-CDR2 comprising SEQ ID NO:14, a Vh-CDR3 comprising SEQ ID NO:15, a Vl-CDR1 comprising SEQ ID NO:115, a Vl-CDR2 comprising SEQ ID NO:116, and a Vl-CDR3 comprising SEQ ID NO:117; a Vh-CDR1 comprising SEQ ID NO:19 comprising, a Vh-CDR2 comprising SEQ ID NO:20, a Vh-CDR3 comprising SEQ ID NO:21, a Vl-CDR1 comprising SEQ ID NO:121, a Vl-CDR2 comprising SEQ ID NO:122, and a Vl-CDR3 comprising SEQ ID NO:123; a Vh-CDR1 comprising SEQ ID NO:25, a Vh-CDR2 comprising SEQ ID NO:26, a Vh-CDR3 comprising SEQ ID NO:27, a Vl-CDR1 comprising SEQ ID NO:127, a Vl-CDR2 comprising SEQ ID NO:128, and a Vl-CDR3 comprising SEQ ID NO:129.

17. A plasmid, comprising the polynucleotide of any of claim 16.

18. The plasmid of claim 17, wherein said plasmid comprises an expression vector.

19. An isolated cell, comprising said plasmid of claim 17, wherein said cell is selected from the group consisting of: a. a prokaryotic cell; b. a eukaryotic cell; c. a mammalian cell; d. an insect cell; and e. a CHO cell.

20. A method of making the antibody of any of claim 1, comprising incubating said isolated cell of claim 19 under conditions that allow it to express said antibody or polypeptide.

21. An isolated antibody, comprising an antibody produced by the CHO cell of claim 19, wherein the antibody comprises a heavy chain encoded by a sequence comprising SEQ ID NO:273 and a light chain encoded by a sequence comprising SEQ ID NO:279.

22. A pharmaceutical composition, comprising the antibody of claim 21.

23. An isolated monoclonal antibody, comprising a monoclonal antibody that binds to SEQ ID NO:352 with a Kd of between 1 nM and 0.01 nM, and binds SEQ ID NO:351 with a Kd of greater than 10 nM.

24. The antibody of claim 23, wherein said antibody is a human monoclonal antibody.

25. The antibody of claim 24, wherein said antibody is an IgG.

26. The antibody of claim 24, wherein said antibody is an IgG1.

Details for Patent 9,243,058

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2032-12-07
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2032-12-07
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2032-12-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.